含有[1,2,4]三唑[1,5- a ]吡啶(I),吡唑并[1,5- a ]吡啶(II),1 H -1,3-苯并二唑(III)和咪唑[设计并合成了1,2- α ]嘧啶(IV)骨架用于PDE10A相互作用。在这些化合物中,1 H -1,3-苯并二唑和咪唑并[1,2- a ]嘧啶类化合物对PDE10A酶的亲和力最高,且代谢稳定性良好。这两类化合物均被鉴定为选择性和有效的PDE10A酶抑制剂。
含有[1,2,4]三唑[1,5- a ]吡啶(I),吡唑并[1,5- a ]吡啶(II),1 H -1,3-苯并二唑(III)和咪唑[设计并合成了1,2- α ]嘧啶(IV)骨架用于PDE10A相互作用。在这些化合物中,1 H -1,3-苯并二唑和咪唑并[1,2- a ]嘧啶类化合物对PDE10A酶的亲和力最高,且代谢稳定性良好。这两类化合物均被鉴定为选择性和有效的PDE10A酶抑制剂。
Neutral weak halothiophene benzimidazole inhibitors of the serine protease factor Xa were identified via screening of a compound library. The X-ray crystal structure of representative 3a bound to human fXa confirmed the S1 binding mode. Starting from 3a a series of halothiophene benzimidazoles was synthesized and investigated for their factor Xa inhibitory activity. This led to potent and selective achiral inhibitors against fXa such as compounds 9k and 9w. (C) 2004 Elsevier Ltd. All rights reserved.
BENZIMIDAZOLDERIVATE
申请人:Merck Patent GmbH
公开号:EP1558247B1
公开(公告)日:2008-02-20
US7566789B2
申请人:——
公开号:US7566789B2
公开(公告)日:2009-07-28
[DE] BENZIMIDAZOLDERIVATE<br/>[EN] BENZIMIDAZOLE DERIVATIVES<br/>[FR] DERIVES DE BENZIMIDAZOLE
申请人:MERCK PATENT GMBH
公开号:WO2004017963A1
公开(公告)日:2004-03-04
Neue verbindungen der formel I Wori D, X, X‘, W, Y, T und R1 die in patentanspruch 1 angegebene Bedeutung haben, Sind inhibitoren des koagulationsfaktors Xa und können zur Prophylaxe und/oder Terapie von thromboembolischen Erkrankungen und zur Behandlung von tumoren eingesetzt werden.